> This collaboration has been established to validate new therapeutic targets and to generate new skincare drug candidates

> First Integrated Drug Discovery Services (IDDS) contract of Oncodesign

> Successful expansion of Oncodesign’s service offering activity following the acquisition of the François Hyafil research center

Access our innovation platform via three offerings: as a service, under a partnership or based on a licensing arrangement

Thanks to its precision medicine platform, Oncodesign is able to orient at a very early stage its research and the development of innovative therapeutic solutions for resistant and unresponsive diseases

For over 20 years, Oncodesign has invested in translational research technologies to bring valuable innovation into the initial phases of the Drug Discovery process.